756. Targeting the Birth-Cohort of the Pre-antibiotic Era;A Proposal to Screen for Tuberculosis in Seniors in Arkansas
Session: Poster Abstract Session: Tuberculosis and Other Mycobacterial Infections
Thursday, October 4, 2018
Room: S Poster Hall
Background:

Approximately 13 million (4.7%) people in the US have Latent TB infection (LTBI). Persons born prior to 1951 have disproportionately higher LTBI prevalence, and frequently experience delays in TB diagnosis and TB deaths. Nevertheless, this birth-cohort was overlooked in the 2016 US Preventive Service Task Force (USPSTF) recommendation for LTBI screening. The aims of this project are to (1) determine the LTBI prevalence in this birth-cohort, (2) assess TB complications prevented by LTBI screening in this birth-cohort, and (3) raise TB awareness among providers and the community.

Methods:

We propose to:

(1) Develop educational pamphlets for the physicians and community.

(2) Screen 10,000 members of the target birth-cohort during their routine clinical visits for one year, using T-SPOT.TB. County health officers, the partners of Arkansas Department of Health, will enroll physicians in their jurisdictions to participate in TB screening. LTBI prevalence in the birth cohort will be determined, and TB complications will be compared among cohort TB cases that were screened to those not previously screened.

(3) Incorporate LTBI and birth-cohort status in patient medical forms.

Results:

In our preliminary study, for the period 2009-2014, 142 of 326 TB cases (43.6% of all US-born TB cases) were reported from the target birth-cohort; 72.6% of the cases had unique genotype strains.

Conclusion:

If the LTBI prevalence in this birth cohort exceeds 8-10%, we recommend a nation-wide screening program for this birth-cohort. Even without treatment, we believe that screening and noting diagnosis of LTBI in the patient record will impact delayed diagnosis and mortality.

Mofan Gu, MPH1, Lori Fischbach, PhD1, Naveen Patil, MD MHSA MA2, Joseph Bates, MD MS2 and Leonard Mukasa, MBChB PhD2, (1)Epidemiology, University of Arkansas for Medical Sciences, Little Rock, AR, (2)Arkansas Department of Health, Little Rock, AR

Disclosures:

M. Gu, None

L. Fischbach, None

N. Patil, None

J. Bates, None

L. Mukasa, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.